Skip to main content

Table 4 Magnitude of use of initial therapy during follow-up, by study cohort

From: Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: A retrospective cohort study

  Schizophrenia Cohort Bipolar Cohort
(N = 43) (N = 84)
Prescriptions   
 Mean (SD) 7.2 (7.4) 4.2 (3.5)
 Median (IQR) 5 (3, 8) 3 (2, 6)
Therapy-days   
 Mean (SD) 100.9 (69.0) 68.3 (60.5)
 Median (IQR) 121 (31,166) 46 (31,115)
MPR   
 <10% 8 (18.6) 20 (23.8)
 10-20% 6 (14.0) 22 (26.2)
 21-30% 1 (2.3) 0 (0.0)
 31-40% 2 (4.7) 7 (8.3)
 41-50% 0 (0.0) 11 (13.1)
 51-60% 2 (4.7) 2 (2.4)
 61-70% 4 (9.3) 6 (7.1)
 71-80% 4 (9.3) 3 (3.6)
 81-90% 6 (14.0) 3 (3.6)
 91-100% 10 (23.3) 10 (11.9)
 Mean (SD) 55.1 (37.7) 37.3 (33.1)
CMG   
 <10% 11 (25.6) 10 (11.9)
 10-20% 8 (18.6) 4 (4.8)
 21-30% 1 (2.3) 2 (2.4)
 31-40% 4 (9.3) 6 (7.1)
 41-50% 2 (4.7) 13 (15.5)
 51-60% 0 (0.0) 1 (1.2)
 61-70% 2 (4.7) 6 (7.1)
 71-80% 1 (2.3) 0 (0.0)
 81-90% 6 (14.0) 22 (26.2)
 91-100% 8 (18.6) 20 (23.8)
Mean (SD) 44.9 (37.7) 62.7 (33.1)
  1. *Unless otherwise indicated, all values are number of patients (%).
  2. MPR: Medication possession ratios; CMG: Cumulative medication gap.